Ageing is the most important risk factor for neurodegenerative diseases, such as Parkinson’s disease (PD), and linked to a progressive decline of molecular, organellar and cellular homeostasis quality control mechanisms. As for other incurable neurodegenerative diseases, mutations in genes responsible for monogenic forms of PD have been identified, that directly interfere with quality control mechanisms that affect (i) molecular quality control, e.g., via protein misfolding and aggregation or (ii) key instances of organellar quality control, e.g., via impaired mitochondrial clearance, and (iii) cellular quality control for selective elimination of damaged cells. To define the missing link between these functional networks, we will dissect mechanisms of quality control surveillance using a unique panel of advanced cellular and animal models of PD and applying novel computational modelling strategies for the identification of complex regulatory networks underlying dysfunctional quality control mechanisms. Based on these novel experimental approaches and advanced screening platforms for in vitroand in vivomodels, we will use pharmacological and genetic interventions to develop novel therapeutic approaches. Our interdisciplinary approach directly synergises with current national research programmes on PD and is envisaged to translate into novel diagnostic and treatment options for neurodegenerative diseases.

PARK-QC - Molecular, Organellar and Cellular Quality Control in Parkinson's disease and Other Neurodegenerative Diseases - is an interdisciplinary doctoral training unit, involving the LCSB, the Department of Life Sciences and Medicine (DLSM), the Luxembourg Institute of Health (LIH) and the Integrated Biobank of Luxembourg (IBBL), funded under the PRIDE scheme of the Luxembourg National Research Fund (FNR).

The training programme focuses on the following research topics

  • Development of advanced disease models addressing different aspects of molecular, organellar and cellular qualitycontrol in neurodegeneration;
  • Identification and integration of molecular mechanisms into networks
  • applying state-of-the-art omics, single-cell and computational modelling technologies;
  • Integrating molecular and cellular signatures into network-based modelling approaches to identify biomarkers for neurodegeneration;
  • Development of experimental readouts to conceptualize novel neuroprotective treatments based on genetic and pharmacological screening.

We offer

  • An enthusiastic interdisciplinary team of computational scientists, clinical researchers and fundamental scientists;
  • An exciting international and multicultural research environment;
  • An interdisciplinary training concept that embeds PhD students into a translational research environment;
  • For more information about research in Luxembourg: EURAXESS

Principal Investigator & Research area



Mittelbronn, Michel


Betsou, Fay 

Biobanking and biomarkers

Sinkkonen, Lasse


Linster, Carole

Repair biochemistry & Metabolomics

del Sol Mesa, Antonio

Computational modelling

Krüger, Rejko

In vitro modelling of Parkinson's disease

Nehrbass, Ulf

In vitro modelling of Parkinson's disease

Schwamborn, Jens

3D brai organoid models for in vitro
disease modelling

Schneider, Reinhard

Data integration and visualisation

Hertel, Frank


Skupin, Alexander

Integrative Cell Signalling

Grünewald, Anne

In vitro modelling of Parkinson's disease


For questions send us an email: